Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors

Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive cancer and may become the second leading cause of cancer death by 2030. About half of the patients are diagnosed late, when the cancer has already spread (mPDAC), and the outlook is very poor. Chemotherapy is currently the only treatment for mPDAC. It can slow the disease and slightly extend life, but usually only by a few months. There are no other treatments that clearly improve survival. Radiofrequency ablation (RFA) is a minimally invasive technique that uses high-frequency electrical energy to generate heat and destroy tumor cel

Trial Details

NCT ID
NCT07191418
Phase
NA
Sponsor
Roberto Valente
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Habib™ EndoHPB
  • ERCP
Locations (sample)
  • Umeå, Sweden|63.82842,20.25972

Key Eligibility Criteria

  • Individuals with newly diagnosed pancreatic cancer in the head of the pancreas causing compression on the bile duct.
  • Metastatic stage to the liver
  • Histologically or cytologically confirmed mPDAC.
  • Cancer burden limited to maximum 5 metastases in the liver, each of them maximum 1 cm in the larger diameter.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →